{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:46:11Z","timestamp":1787319971424,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"European Innovation Council Accelerator","award":["947081"],"award-info":[{"award-number":["947081"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"DOI":"10.1007\/s00408-026-00881-3","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T06:53:26Z","timestamp":1774335206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Effect of the Novel Macrolide Glasmacinal (EP395) on Allergen-Induced Eosinophil Infiltration into the Lung"],"prefix":"10.1007","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-1936","authenticated-orcid":false,"given":"Jennifer A.","family":"Kricker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2137-9430","authenticated-orcid":false,"given":"Yanira","family":"Riffo-Vasquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-3799","authenticated-orcid":false,"given":"Clive P.","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7098-8451","authenticated-orcid":false,"given":"Michael J.","family":"Parnham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"10095","key":"881_CR1","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","volume":"390","author":"PG Gibson","year":"2017","unstructured":"Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL et al (2017) Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet 390(10095):659\u2013668. https:\/\/doi.org\/10.1016\/S0140-6736(17)31281-3","journal-title":"Lancet"},{"issue":"8","key":"881_CR2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMoa1104623","volume":"365","author":"RK Albert","year":"2011","unstructured":"Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr., Criner GJ et al (2011) Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365(8):689\u2013698. https:\/\/doi.org\/10.1056\/NEJMoa1104623","journal-title":"N Engl J Med"},{"issue":"5","key":"881_CR3","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/thoraxjnl-2019-213929","volume":"75","author":"D Smith","year":"2020","unstructured":"Smith D, Du Rand I, Addy CL, Collyns T, Hart SP, Mitchelmore PJ et al (2020) British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. Thorax 75(5):370\u2013404. https:\/\/doi.org\/10.1136\/thoraxjnl-2019-213929","journal-title":"Thorax"},{"key":"881_CR4","doi-asserted-by":"publisher","first-page":"102364","DOI":"10.1016\/j.pupt.2025.102364","volume":"90","author":"JA Kricker","year":"2025","unstructured":"Kricker JA, Norris V, Page C, Parnham MJ (2025) Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation. Pulm Pharmacol Ther 90:102364. https:\/\/doi.org\/10.1016\/j.pupt.2025.102364","journal-title":"Pulm Pharmacol Ther"},{"key":"881_CR5","doi-asserted-by":"publisher","first-page":"102365","DOI":"10.1016\/j.pupt.2025.102365","volume":"90","author":"JM Hohlfeld","year":"2025","unstructured":"Hohlfeld JM, Badorrek P, Breuer O, Hanrott K, Kricker J, Parnham MJ, Norris V (2025) Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial. Pulm Pharmacol Ther 90:102365. https:\/\/doi.org\/10.1016\/j.pupt.2025.102365","journal-title":"Pulm Pharmacol Ther"},{"key":"881_CR6","doi-asserted-by":"publisher","unstructured":"Watz H, Korn S, Kornmann O, Singh D, Wilkinson T, Hanrott K, et al (2025) A randomised controlled trial of EP395, a novel anti-inflammatory macrolide, in stable COPD patients ERJ Open Research (in press). https:\/\/doi.org\/10.1183\/23120541.00782-2025","DOI":"10.1183\/23120541.00782-2025"},{"key":"881_CR7","unstructured":"GOLD Scientific Committee (2024) Global Initiative for Chronic Obstructive Lung Disease (GOLD) Committee Report. https:\/\/goldcopd.org\/2024-gold-report\/"},{"issue":"5","key":"881_CR8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1165\/ajrcmb.22.5.f183","volume":"22","author":"MJ Madison","year":"2000","unstructured":"Madison MJ, Schramm CM (2000) Cationic proteins and bronchial hyperresponsiveness. Am J Respir Cell Mol Biol 22(5):513\u2013516. https:\/\/doi.org\/10.1165\/ajrcmb.22.5.f183","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"881_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2500\/aap.2013.34.3628","volume":"34","author":"DM Rose","year":"2013","unstructured":"Rose DM, Hrncir DE (2013) Primary eosinophilic lung diseases. Allergy Asthma Proc 34(1):19\u201325. https:\/\/doi.org\/10.2500\/aap.2013.34.3628","journal-title":"Allergy Asthma Proc"},{"issue":"6 Pt 2","key":"881_CR10","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/0091-6749(94)90333-6","volume":"94","author":"RP Schleimer","year":"1994","unstructured":"Schleimer RP, Bochner BS (1994) The effects of glucocorticoids on human eosinophils. J Allergy Clin Immunol 94(6 Pt 2):1202\u20131213. https:\/\/doi.org\/10.1016\/0091-6749(94)90333-6","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"881_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40272-025-00694-6","volume":"27","author":"ME Di Cicco","year":"2025","unstructured":"Di Cicco ME, Peroni D, Marseglia GL, Licari A (2025) Unveiling the complexities of pediatric asthma treatment: evidence, controversies, and emerging approaches. Paediatr Drugs 27(4):393\u2013404. https:\/\/doi.org\/10.1007\/s40272-025-00694-6","journal-title":"Paediatr Drugs"},{"issue":"7","key":"881_CR12","doi-asserted-by":"publisher","first-page":"CD009471","DOI":"10.1002\/14651858.CD009471.pub2","volume":"2014","author":"L Zhang","year":"2014","unstructured":"Zhang L, Prietsch SO, Ducharme FM (2014) Inhaled corticosteroids in children with persistent asthma: effects on growth. Cochrane Database Syst Rev 2014(7):CD009471. https:\/\/doi.org\/10.1002\/14651858.CD009471.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"881_CR13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s40266-014-0213-1","volume":"31","author":"S Battaglia","year":"2014","unstructured":"Battaglia S, Cardillo I, Lavorini F, Spatafora M, Scichilone N (2014) Safety considerations of inhaled corticosteroids in the elderly. Drugs Aging 31(11):787\u2013796. https:\/\/doi.org\/10.1007\/s40266-014-0213-1","journal-title":"Drugs Aging"},{"issue":"1","key":"881_CR14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12931-019-1213-9","volume":"20","author":"S Langham","year":"2019","unstructured":"Langham S, Lewis J, Pooley N, Embleton N, Langham J, Han MK, Chalmers JD (2019) Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review. Respir Res 20(1):242. https:\/\/doi.org\/10.1186\/s12931-019-1213-9","journal-title":"Respir Res"},{"issue":"1","key":"881_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","volume":"177","author":"JA Wedzicha","year":"2008","unstructured":"Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA, Investigators I (2008) The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177(1):19\u201326. https:\/\/doi.org\/10.1164\/rccm.200707-973OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"881_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/imr.13380","volume":"328","author":"A Eggel","year":"2024","unstructured":"Eggel A, Pennington LF, Jardetzky TS (2024) Therapeutic monoclonal antibodies in allergy: targeting IgE, cytokine, and alarmin pathways. Immunol Rev 328(1):387\u2013411. https:\/\/doi.org\/10.1111\/imr.13380","journal-title":"Immunol Rev"},{"issue":"10516","key":"881_CR17","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/S0140-6736(25)01625-3","volume":"406","author":"E Israel","year":"2025","unstructured":"Israel E, Wechsler ME, Jackson DJ, Moore WC (2025) Anti-cytokine biologics for asthma in adults. Lancet 406(10516):2282\u20132294. https:\/\/doi.org\/10.1016\/S0140-6736(25)01625-3","journal-title":"Lancet"},{"key":"881_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.rmed.2019.06.005","volume":"154","author":"RS Djamin","year":"2019","unstructured":"Djamin RS, Bafadhel M, Uzun S, Russell REK, Ermens AAM, Kerstens R et al (2019) Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations. Respir Med 154:27\u201333. https:\/\/doi.org\/10.1016\/j.rmed.2019.06.005","journal-title":"Respir Med"},{"issue":"2","key":"881_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/thorax-2024-221977","volume":"80","author":"G Lavoie","year":"2025","unstructured":"Lavoie G, Howell I, Melhorn J, Borg C, Bermejo-Sanchez L, Seymour J et al (2025) Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment. Thorax 80(2):113\u2013116. https:\/\/doi.org\/10.1136\/thorax-2024-221977","journal-title":"Thorax"},{"key":"881_CR20","doi-asserted-by":"publisher","first-page":"e52005","DOI":"10.3791\/52005","volume":"92","author":"H Evans","year":"2014","unstructured":"Evans H, Killoran KE, Mitre E (2014) Measuring local anaphylaxis in mice. J Vis Exp 92:e52005. https:\/\/doi.org\/10.3791\/52005","journal-title":"J Vis Exp"},{"key":"881_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3389\/fmed.2017.00093","volume":"4","author":"CN McBrien","year":"2017","unstructured":"McBrien CN, Menzies-Gow A (2017) The biology of eosinophils and their role in asthma. Front Med (Lausanne) 4:93. https:\/\/doi.org\/10.3389\/fmed.2017.00093","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"881_CR22","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","volume":"184","author":"M Bafadhel","year":"2011","unstructured":"Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P et al (2011) Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 184(6):662\u2013671. https:\/\/doi.org\/10.1164\/rccm.201104-0597OC","journal-title":"Am J Respir Crit Care Med"},{"key":"881_CR23","doi-asserted-by":"publisher","first-page":"102363","DOI":"10.1016\/j.pupt.2025.102363","volume":"90","author":"T Gudjonsson","year":"2025","unstructured":"Gudjonsson T, Joelsson JP, Arason AJ, Asbjarnarson A, Gardarsson FR, Lehmann F et al (2025) A novel macrolide, EP395, with reduced antibacterial activity and an enhancing effect on respiratory epithelial barrier. Pulm Pharmacol Ther 90:102363. https:\/\/doi.org\/10.1016\/j.pupt.2025.102363","journal-title":"Pulm Pharmacol Ther"},{"issue":"2","key":"881_CR24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.pharmthera.2014.03.003","volume":"143","author":"MJ Parnham","year":"2014","unstructured":"Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R (2014) Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther 143(2):225\u2013245. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.03.003","journal-title":"Pharmacol Ther"},{"key":"881_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052287","author":"A Asbjarnarson","year":"2025","unstructured":"Asbjarnarson A, Joelsson JP, Gardarsson FR, Sigurdsson S, Parnham MJ, Kricker JA, Gudjonsson T (2025) The non-antibacterial effects of Azithromycin and other macrolides on the bronchial epithelial barrier and cellular differentiation. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26052287","journal-title":"Int J Mol Sci"},{"issue":"1","key":"881_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12931-020-01489-8","volume":"21","author":"JP Joelsson","year":"2020","unstructured":"Joelsson JP, Kricker JA, Arason AJ, Sigurdsson S, Valdimarsdottir B, Gardarsson FR et al (2020) Azithromycin ameliorates sulfur dioxide-induced airway epithelial damage and inflammatory responses. Respir Res 21(1):233. https:\/\/doi.org\/10.1186\/s12931-020-01489-8","journal-title":"Respir Res"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-026-00881-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-026-00881-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-026-00881-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T06:53:28Z","timestamp":1774335208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-026-00881-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["881"],"URL":"https:\/\/doi.org\/10.1007\/s00408-026-00881-3","relation":{},"ISSN":["1432-1750"],"issn-type":[{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial interests: Authors J.A.K., M.J.P., and V.N. are employees of EpiEndo Pharmaceuticals. Authors J.A.K., M.J.P., V.N., and C.P.P. are either shareholders or have options in EpiEndo Pharmaceuticals. C.P.P. also declares he has received consultancy and speaker fees from Recipharm and Eurodrug; he is also an NED and has equity in Ananda Pharma. Author Y.R.F. declares they have no financial interests. M.J.P. teaches at and receives travel expenses from Goethe University Frankfurt, is a co-founder of and holds equity in Phialogics AG and is a shareholder in Cyclone Therapeutics Inc. and Oxford Biomedica plc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"These studies were performed in line with the principles of the Declaration of Helsinki. The study involving guinea pigs was reviewed and approved by the local Animal Welfare and Ethical Review Board (AWERB) of King\u2019s College London and experiments were carried out under UK Home Office Project Licence PP2935715 in strict accordance with the Animals Act 1986 and the ARRIVE guidelines. Studies in mice were carried out at Pharmidex in the UK covered by a UK Home Office Project Licence P8AE03703 and followed pre-prepared protocols. The study involving guinea pigs was also approved.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}],"article-number":"17"}}